Glucagon Hydrochloride

Summary

Glucagon Hydrochloride (CHEMBL5314342) is an approved protein; indicated across 3 conditions including diabetes mellitus and hypoglycemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 3 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314342
Name	Glucagon Hydrochloride
Type	Protein
Max phase	4

Also known as: Glucagen, Glucagon chloride, Glucagon hcl, Glucagon hydrochloride, Glucagon hydrochloride recombinant, Glucagon, monohydrochloride, GLUCAGON HYDROCHLORIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	3	MONDO:0005015	EFO:0000400
hypoglycemia	2	MONDO:0004946	HP:0001943
type 2 diabetes mellitus	1	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	2
Not specified	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03216226	PHASE3	COMPLETED	A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
NCT03378635	PHASE3	COMPLETED	A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
NCT03667053	PHASE3	COMPLETED	Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
NCT02660008	PHASE2	COMPLETED	Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon
NCT05454709	PHASE2	WITHDRAWN	A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System
NCT00745186	PHASE1	COMPLETED	Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers
NCT05076292	Not specified	COMPLETED	Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes
NCT05379686	Not specified	COMPLETED	Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).